Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer - Zhao, Na; Cao, Jin; Xu, Longyong; Tang, Qianzi; Dobrolecki, Lacey E.; Lv, Xiangdong; Talukdar, Manisha; Lu, Yang; Wang, Xiaoran; Hu, Dorothy Z.; Shi, Qing; Xiang, Yu; et al. (The Journal of clinical investigation, 2018)
Keywords: Activating transcription factor 1; Animal models; Animals; Biomedical research; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Breast Neoplasms - pathology; Cancer therapies; Cancer treatment; Care and treatment; Cell Line, Tumor; Chemotherapy; Development and progression; Docetaxel - pharmacology; Drug Delivery Systems; Endoplasmic reticulum; Endoribonucleases - genetics; Endoribonucleases - metabolism; Enzymes; Female; Genes; Genetic aspects; Genetic engineering; Health aspects; Humans; Inositol; Kinases; Mice; Molecular modelling; Myc protein; Nucleotidases; Pharmacological research; Phosphorylation; Physiological aspects; Protein folding; Protein-Serine-Threonine Kinases - genetics; Protein-Serine-Threonine Kinases - metabolism; Proteins; Proto-Oncogene Proteins c-myc - genetics; Proto-Oncogene Proteins c-myc - metabolism; Response Elements; Ribonuclease; Saccharomyces cerevisiae; Signal Transduction - drug effects; Signal Transduction - genetics; Stem cells; Transcription; Transcription factors; Tumors; Unfolded Protein Response - drug effects; Unfolded Protein Response - genetics; X-Box Binding Protein 1 - genetics; X-Box Binding Protein 1 - metabolism; Xenograft Model Antitumor Assays; Xenografts; United States--US; Oncology; Breast cancer; Cell stress; Drug therapy; Therapeutics